We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+2.14%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.51B
AUM Growth
-$1.16B
Cap. Flow
+$107M
Cap. Flow %
1.43%
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$165M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$119M
3
ACLX
Arcellx
ACLX
+$80.8M
4
KURA icon
Kura Oncology
KURA
+$64M
5
JANX icon
Janux Therapeutics
JANX
+$63.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$230M
2
VRNA
Verona Pharma
VRNA
+$122M
3
EVH icon
Evolent Health
EVH
+$86.8M
4
CGON icon
CG Oncology
CGON
+$52.7M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.36%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZURA icon
76
Zura Bio
ZURA
$541M
$8.04M 0.11%
3,217,503
– –
PCSC
77
DELISTED
Perceptive Capital Solutions
PCSC
$7.63M 0.1%
750,000
– –
BIOA
78
BioAge Labs
BIOA
$498M
$7.59M 0.1%
1,310,589
-900,000
-41% -$15.5M
ACET icon
79
Adicet Bio
ACET
$86.1M
$7.25M 0.1%
471,313
– –
AVTX icon
80
Avalo Therapeutics
AVTX
$980M
$7.18M 0.1%
967,000
– –
BOLD
81
Boundless Bio
BOLD
$60.9M
$6.32M 0.08%
2,180,631
– –
ENTA icon
82
Enanta Pharmaceuticals
ENTA
$387M
$5.97M 0.08%
+1,038,000
New +$9.95M
NAMSW icon
83
NewAmsterdam Pharma Warrant
NAMSW
$69M
$4.75M 0.06%
333,333
– –
SRZN icon
84
Surrozen
SRZN
$255M
$4.06M 0.05%
282,580
– –
LXEO icon
85
Lexeo Therapeutics
LXEO
$346M
$3.6M 0.05%
546,554
– –
ALLK
86
DELISTED
Allakos
ALLK
$1.37M 0.02%
+1,129,931
New +$1.19M
SRRK icon
87
Scholar Rock
SRRK
$5.73B
$761K 0.01%
+17,616
New +$574K
RGLS
88
DELISTED
Regulus Therapeutics
RGLS
$532K 0.01%
336,843
-429,991
-56% -$661K
SCLX icon
89
Scilex Holding
SCLX
$45.5M
$442K 0.01%
29,606
+22,144
+297% +$563K
ANTX icon
90
AN2 Therapeutics
ANTX
$214M
– –
-1,999,997
Closed -$2.14M
BIIB icon
91
Biogen
BIIB
$30.8B
– –
-1,184,456
Closed -$230M
CGON icon
92
CG Oncology
CGON
$6.3B
– –
-1,397,433
Closed -$52.7M
CRVO icon
93
CervoMed
CRVO
$25.9M
– –
-817,120
Closed -$11.9M
NUVL
94
DELISTED
Nuvalent
NUVL
– –
-176,281
Closed -$18M
TNYA icon
95
Tenaya Therapeutics
TNYA
$161M
– –
-6,982,587
Closed -$13.5M
ANRO icon
96
Alto Neuroscience
ANRO
$1.1B
– –
-2,075,154
Closed -$23.7M
MGX icon
97
Metagenomi Therapeutics
MGX
$45.6M
– –
-1,305,239
Closed -$2.83M
ADGM
98
Adagio Medical Holdings
ADGM
$17.8M
– –
-1,333,926
Closed -$3.44M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, RA Capital Management held 98 positions worth $7.51B, down 13% from $8.67B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management's Q4 2024 filing shows 17 new, 9 increased, 16 reduced and 9 closed positions. Its largest new stake was Septerna Inc: 6,995,858 shares worth $160M. The largest sale was Biogen, an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q4 2024 buy was Septerna Inc: 6,995,858 shares worth $160M.
  • RA Capital Management added most to Arcellx in Q4 2024, an estimated $80.8M increase.
  • RA Capital Management's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $122M.
  • RA Capital Management fully exited Biogen in Q4 2024, selling an estimated $230M.
  • RA Capital Management's ten largest holdings make up 58% of its $7.51B portfolio in Q4 2024.
  • RA Capital Management opened 17 new positions and closed 9 in Q4 2024.
  • RA Capital Management's portfolio value fell 13% quarter-over-quarter to $7.51B.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.